english.prescrire.org > Spotlight > 100 most recent > Intravitreal VEGF inhibitors: systemic adverse effects

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Intravitreal VEGF inhibitors: systemic adverse effects

 Adverse Effects  A pharmacovigilance survey carried out by the French Health Products Agency (ANSM) identified 130 reports of cardiovascular adverse effects, mainly stroke, in patients treated with an intravitreal VEGF inhibitor. Two epidemiological studies, one conducted in the US and the other in Taiwan, quantified the risk of cardiovascular or kidney disease associated with intravitreal exposure to VEGF inhibitors.
Full article available for download by subscribers

 ©Prescrire 1 February 2025

Source: "Intravitreal VEGF inhibitors: cardiovascular and renal adverse effects" Prescrire Int 2025; 34 (267): 48. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook Share on  Twitter
 
 
See also:

"Intravitreal ranibizumab,
bevacizumab and aflibercept:
thrombosis"
Prescrire Int 2018;
27 (189): 17-19.
Subscribers only